DLK1/PREF1 regulates nutrient metabolism and protects from steatosis. by Charalambous, Marika et al.
DLK1/PREF1 regulates nutrient metabolism and
protects from steatosis
Marika Charalambousa,1,2, Simao Teixeira Da Rochaa,3, Elizabeth Jane Radforda, Gema Medina-Gomezb,4,
Scott Currana,5, Scarlett B. Pinnocka, Sacri R. Ferróna,6, Antonio Vidal-Puigb, and Anne C. Ferguson-Smitha,1,7
aDepartment of Physiology, Development and Neuroscience, University of Cambridge, Cambridge CB2 3EG, United Kingdom; and bMetabolic Research
Laboratories, Wellcome Trust and Medical Research Council Institute of Metabolic Science, Addenbrooke’s Hospital, University of Cambridge, Cambridge CB2
2QR, United Kingdom
Edited by Ethan Weiss, University of California, San Francisco, CA, and accepted by the Editorial Board October 2, 2014 (received for review April 4, 2014)
Nonalcoholic fatty liver disease (NAFLD) is associated with insulin
resistance and obesity, as well as progressive liver dysfunction.
Recent animal studies have underscored the importance of hepatic
growth hormone (GH) signaling in the development of NAFLD. The
imprinted Delta-like homolog 1 (Dlk1)/preadipocyte factor 1 (Pref1)
gene encodes a complex protein producing both circulating and
membrane-tethered isoforms whose expression dosage is function-
ally important because even modest elevation during embryogene-
sis causes lethality. DLK1 is up-regulated during embryogenesis,
during suckling, and in the mother during pregnancy. We investi-
gated the normal role for elevated DLK1 dosage by overexpressing
Dlk1 from endogenous control elements. This increased DLK1 dos-
age caused improved glucose tolerance with no primary defect in
adipose tissue expansion even under extreme metabolic stress.
Rather, Dlk1 overexpression caused reduced fat stores, pituitary
insulin-like growth factor 1 (IGF1) resistance, and a defect in feedback
regulation of GH. Increased circulatory GH culminated in a switch in
whole body fuel metabolism and a reduction in hepatic steatosis. We
propose that the function of DLK1 is to shift themetabolic mode of the
organism toward peripheral lipid oxidation and away from lipid stor-
age, thus mediating important physiological adaptations associated
with early life and with implications for metabolic disease resistance.
Delta-like homologue 1 | hepatosteatosis | genomic imprinting |
growth hormone | adipose tissue
Hepatosteatosis or nonalcoholic fatty liver disease (NAFLD) isthe accumulation of hepatic triglyceride (TAG) and results
from excessive fatty-acid (FA) synthesis relative to oxidative
clearance and/or elevated adipose tissue lipid hydrolysis (reviewed
in ref. 1). FA synthesis, clearance, and release are regulated by
neuroendocrine factors including GH, whose levels vary under
conditions of changing energy supply (2). Recent animal studies
have underscored the important role of hepatic GH signaling in
the development of NAFLD and the metabolic syndrome (3–6).
The Delta-like homolog 1 (Dlk1) gene encodes a single pass
membrane protein that is homologous to the Notch pathway ligand
Delta but lacks canonical Notch interaction sequences (7–9). DLK1
was described simultaneously by several groups before it was iden-
tified as the product of a single gene (9–11), and, consequently, it is
also referred to as fetal antigen 1 (FA1) and preadipocyte factor 1
(PREF1). Dlk1 encodes a complex protein that can produce both
cleaved (circulating) and membrane-tethered isoforms, a result of
alternative splicing (12). Consequences of Dlk1 overexpression have
been explored previously in a limited isoform-specific and/or tissue-
specific manner. For example, ectopic overproduction of the
cleaved ectodomain of DLK1 causes a lipodystrophic phenotype
associated with triglyceride deposition and glucose intolerance (13,
14). However, recent work has shown that tightly regulated dosage
control of both forms is crucial for its biological function (15–17).
The expression of Dlk1 is highly dynamic. Indeed, as an im-
printed gene, Dlk1 is subject to multiple levels of epigenetic dosage
control beyond conventional mechanisms of tissue- and temporal-
specific regulation (7, 8). The expression dosage of Dlk1 is func-
tionally important because even modest elevation of normal Dlk1
transcription during embryogenesis is incompatible with the
completion of intrauterine development (18), and modulation of
expression in a stem-cell niche can profoundly alter the self-enewal
properties of cells (16). Importantly, circulating and membrane-
tethered DLK1 levels are normally physiologically up-regulated
during embryogenesis (19), during suckling (20, 21), and in the
mother during pregnancy (20). The normal function of this dy-
namic DLK1 dosage modulation during these periods is not known.
Here, we show that, in contrast to previous Dlk1 tissue and
splice form overexpression models (13, 14), Dlk1 overexpression
from endogenous control elements causes improved whole-body
glucose homeostasis with no primary defect in adipose-tissue
expansion, even under extreme metabolic stress. This surprising
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finding challenges the current dogma that the normal function of
DLK1 is to negatively regulate adipogenesis. Moreover, in both
a genetic and a dietary model of positive energy balance, DLK1-
overexpressing mice were resistant to steatosis, primarily due to
a reduction of hepatic lipid synthesis and an increase in skeletal
muscle lipid oxidation. Moreover, we found that DLK1-over-
expressing mice had elevated production of pituitary growth hor-
mone due to a local defect in IGF1 feedback. Because impaired
GH signaling is known to cause steatosis by affecting pathways of
hepatic lipid import and synthesis (3–5), as well affecting peripheral
FA oxidation (22), we propose that increased dosage of DLK1 acts
primarily on the GH axis to shift the metabolic mode toward FA
oxidation, with overall beneficial effects on hepatic lipid deposition.
Results
A 70-kb Transgene Overexpresses Dlk1 in an Authentic Isoform-Specific
and Spatiotemporal Manner. We used a BAC transgenic model
containing the Dlk1 gene within 70 kb of the surrounding se-
quence and generated three independent transgenic lines (70A,
70B, and 70C) (18). Postnatally, Dlk1 is expressed in the adrenal
gland (23), the somatotrophs of the pituitary (24), in a small
number of cells in the brain (25), and in stromal-vascular cell
populations associated with muscle and adipose tissues (11, 26,
27). Dlk1-transgenic hemizygous animals (WT/TG) recapitulated
this postnatal restriction of Dlk1 expression, (Fig. 1 A and B and
Fig. S1). Moreover, the proportion of transcripts encoding cleav-
able (A and B) to membrane-tethered (C and D) DLK1 in adult
organs was similar in tissues from transgenic mice compared with
their WT littermates (Fig. S1). Finally, we measured the amount of
cleaved DLK1 ectodomain in the serum of adult mice (Fig. 1C). We
found that DLK1 levels were elevated in the three transgenic lines to
a similar extent (185–387 ng/mL) and four- to sevenfold compared
with the WT adults (∼54 ng/mL). This level is similar to that found
in maternal serum in late pregnancy of rodents and humans (20, 28).
We concluded that the presence of the transgene in the 70A to -C
lines resulted in normally localized but elevated isoform and tem-
poral-specific expression of Dlk1, with no ectopic expression.
Overexpression of Dlk1 Limits Accumulation of White Adipose Tissue,
with No Evidence for Failure of Adipogenesis, and Improves Glucose
Tolerance and Whole-Body Insulin Sensitivity. WT/TG mice accu-
mulated white adipose tissue (WAT) at a slower rate than their
WT littermates (Fig. 2A), and, at 6 mo of age, had significantly
reduced gonadal, renal, and interscapular fat stores in both sexes
(Fig. 2A and Table S1). WT/TG mice of both sexes maintained an
∼10% reduction in total body weight up to 1 y of age (Fig. S2A),
and the reduction in body weight was attributable to a reduction in
both lean and adipose mass, but not skeletal parameters such as
length and bone density (Fig. S2B). The relative weight reduction
was not due to reduced food intake (Fig. S2C).
Histologically the adipose cell size in WT/TG animals was
reduced, and the proportion of small fat cells was increased (Fig.
2B). Elevated levels of the cleaved ectodomain of DLK1 in vitro
and in vivo has been correlated with reduced expression of the
key adipogenic gene Pparγ (12, 13). Surprisingly we did not ob-
serve a reduction in either Pparγ1 or Pparγ2 expression in WAT
from WT/TG animals compared with their WT littermates (Fig.
2C). Consistent with this finding, we found no evidence of im-
paired adipogenesis, such as reduced expression of markers of
mature fat such as the fatty acid binding protein 4 (aP2), the
insulin-sensitive glucose transporter (Glut4), or lipoprotein lipase
(Lpl). Gene expression of markers associated with brown or beige
fat (Pgc1α and Pgc1β, Ucp1), beta oxidation (Pparα), or uncoupling
(Ucp2) were also not affected by Dlk1 overexpression. In contrast,
the expression of genes normally positively regulated by insulin,
sterol receptor binding protein 1c (Srebp1c), steroyl-coA desaturase
(Scd1), and fatty acid synthase (Fas) were all increased in WT/TG
animals (Fig. 2C). These gene expression changes were not sec-
ondary to elevated circulating insulin levels (Table S2), indicating
that WT/TG adipose tissue may instead have increased insulin
sensitivity. In addition, the reduction in circulating leptin levels
observed in WT/TG animals (Table S2) was consistent with their
reduced WAT stores but cannot account for the differences in the
expression of lipogenic genes in WAT (29). WT/TG mice had
normal circulating levels of adiponectin and resistin (Table S2),
suggesting that the alterations we observed in insulin sensitivity were
not secondary to altered levels of these adipokines.
We concluded that overexpression of Dlk1 in the context of its
normal regulatory environment does not cause primary lipo-
dystrophy because adipose differentiation pathways were not
impaired, insulin sensitivity was increased, and there was no
evidence of ectopic adipose deposition either in the liver or in
skeletal muscle (Table S2). This finding was supported by an
Fig. 1. A 70-kb transgene overexpresses Dlk1 in an authentic isoform-specific
and spatiotemporal manner. (A) Real-time quantitative PCR (RT qPCR) of total
Dlk1 transcripts in adult tissue. (B) Western blotting of an intracellular epi-
tope of DLK1 in WT tissues (Left), ∼50 kDa both membrane-bound and
cleaved ectodomain in pituitary (pit), whole e16 embryo (emb), and adrenal
(adr); <20 kDa band is the membrane-bound remnant of cleavage. (Right)
Relative protein expression between WT and WT/TG animals (70C line) in pit
and adr samples (run on separate gels). (C) Serum levels of cleaved DLK1
ectodomain in adult mice from three transgenic lines and WT measured by
ELISA (females at 6 mo of age,mean± SEM). Numbers above the columns show
concentrations relative to WT. WT, n = 10; 70A, n = 4; 70B, n = 3; 70C, n = 9.
Fig. 2. Overexpression of Dlk1 limits accumulation of WAT, with no evi-
dence for failure of adipogenesis, and improves glucose tolerance and
whole-body insulin sensitivity. (A) Abdominal WAT accumulation in female
mice from 1–6 mo of age 70B mice and WT littermates (n > 3 per time per
genotype), P < 0.001 overall by one-way ANOVA, and at each time point by
Bonferroni’s multiple comparison post hoc test, *P < 0.05, **P < 0.01. (B,
Upper) Representative H&E staining of epididymal WAT from 26-wk-old
mice. (Lower) Percent relative cumulative frequency (PRCF) analysis (PCRF,
n = 4 mice per genotype). (C) RT-qPCR of WAT genes from abdominal WAT
at 6 mo (data from 70B free-fed male mice), normalized to reference gene
expression and then presented relative to WT = 1.0. WT and WT/TG, *P <
0.05 by Mann–Whitney U test, n = 6 per genotype, *P < 0.05. Glucose tol-
erance test (GTT) (D) and insulin tolerance test (ITT) (E) on 6-mo-old male
mice from the 70B line. *P < 0.05 and **P < 0.01 by one-way ANOVA with
Bonferroni’s post hoc test; WT, n = 13; WT/TG, n = 8. Values are mean ± SEM.











overall improvement in glucose tolerance and whole-body insulin
sensitivity in WT/TG adults (Fig. 2 D and E). In the fed state,
circulating lipid levels were not different between WT and WT/
TG animals. However, in fasted animals, serum free-fatty acids
(FFAs) and glycerol were elevated (Table S2), suggesting that,
when insulin levels were low, the rate of WAT lipolysis was in-
creased in WT/TG animals. An elevated rate of WAT lipolysis
could therefore account for the reduced adipocyte cell and depot
size that we observed in Dlk1-TG mice.
Dlk1-Overexpressing Mice Are Capable of Adipose Expansion and Are
Resistant to Hepatosteatosis, on an Obesogenic Genetic Background.
Overexpression of the cleaved form of DLK1 from an adipocyte-
or hepatocyte-specific promoter has previously been shown to
result in impaired fat expansion and misexpression of adipogenic
genes, with reduced glucose tolerance and insulin resistance (13,
14). In contrast, our model of isoform and tissue-authentic
overexpression did not show impairments in WAT adipogenic
gene expression, and glucose homeostasis was improved. To test
whether we had missed a defect in adipose expandability in the
Dlk1-TG mice, we measured their body composition and other
metabolic parameters in the context of extreme positive energy
balance. We hypothesized that, if increased DLK1 from the
transgene impairs adipose tissue expandability, WT/TG mice
would have reduced WAT mass, and potentially increased ectopic
lipid storage with associated impairments in glucose tolerance,
compared with WT when crossed onto the hyperphagic ob/ob
background. Surprisingly WT/TG ob/ob animals gained weight at
the same rate as WT ob/ob littermates and, at 6 mo, had identical
body composition (Fig. 3 A–C). Similar to WT ob/ob mice, WT/
TG ob/ob mice were hyperglycemic and hyperinsulinemic, but
there was no exacerbation of the glucose intolerance, as would be
expected if overdose of DLK1 caused lipodystrophy (Table S3).
We therefore concluded that overexpression of Dlk1 from en-
dogenous control elements does not compromise adipose ex-
pandability in the face of extreme positive energy balance.
Leptin is known to inhibit hepatic lipogenesis by suppression
of Srepb1c, a transcriptional regulator of lipogenic genes (30).
Alleviation of this Srebp1c suppression, in concert with hyper-
insulinemia in ob/ob mice causes hepatosteatosis (31), which we
observed in livers from WT ob/ob mice. Surprisingly, WT/TG
mice did not develop hepatosteatosis. Instead, WT/TG ob/ob
livers were less enlarged (Fig. 3D) and exhibited much reduced
lipid deposition than WT ob/ob littermates. Furthermore, WT/TG
ob/ob livers seemed healthy, with normal zonation, and we ob-
served no evidence of fibrosis (Fig. 3E).
Elevated DLK1 Protects Against High Fat Diet-Induced Steatosis by
Decreasing Hepatic Lipogenesis. To explore the protective role of
DLK1 in hepatosteatosis further, male TG mice and WT litter-
mates were fed a 45% fat diet [high-fat diet (HFD)] from 4 wk to
24 wk. At 6 mo of age, WT/TG mice were significantly smaller
than WT due to a reduction in both lean and adipose mass
(Table S4). The HFD regimen led to fasting hyperglycemia,
hyperinsulinemia (Table S5), and marked steatosis in the livers
of WT mice (Fig. 4A), with associated elevation of lipogenic gene
expression compared with chow-fed mice (Fig. 4B). Although the
WT/TG mice on the HFD developed similarly raised levels of
fasting glucose and insulin (Table S5), the liver was devoid of
large lipid droplets (Fig. 4A), and the total TAG content was
significantly reduced (WT, 210 ± 50 mg/g tissue; WT/TG, 89 ±
12 mg/g tissue, n = 7 per genotype, P = 0.026, Mann–Whitney U
test). Serum levels of alanine aminotransferase (ALT), a marker
of hepatocyte damage (Table S5), in WT/TG were low compared
with the high levels observed in WT animals. WT/TG mice on
a HFD had reduced expression of the lipid transporter Cd36 and
of lipogenic pathway genes. Consistently, levels of CD36 and
FAS protein were also reduced (Fig. 4C). Importantly, Pparγ2
was refractory to induction by the HFD (Fig. 4B), indicating that
DLK1 inhibits hepatic triglyceride deposition by preventing in-
duction of the de novo lipogenesis pathway.
The effect of DLK1 overexpression was specific to the
lipogenic transcriptional response because we did not see
a difference between WT and WT/TG animals in the expression
levels of genes in the gluconeogenic (Pgc1α, PEPCK, and Igfbp1)
or lipid oxidation pathways (Cpt1α and -1β, Pparα). Further-
more, these genes responded appropriately to elevated insulin in
both genotypes (Fig. 4D). The proximal insulin-signaling path-
way did not seem to be affected by elevated DLK1 because in-
sulin stimulation led to equal levels of AKT phosphorylation in
both WT and WT/TG livers (Fig. S3). Finally, elevated DLK1
was associated with improved glucose tolerance and whole-body
insulin sensitivity on a HFD (Fig. 4 E and F), which was not
secondary to alterations in circulating adipokine levels (Table
S5). Together these findings indicate that DLK1 acts specifically
on the lipogenesis pathway without impairment of hepatic insulin
sensitivity or altered adipokine production.
Increasing DLK1 Dosage Causes Increased Pituitary GH Secretion.
Hepatic GH signaling can protect the liver from steatosis (3–
6). Depletion of hepatic GH signaling is thought to cause ac-
cumulation of triglycerides in the liver in two ways. Firstly, ab-
lation of GH signaling in the liver itself prevents suppression of
the fatty acid translocase Cd36, and Pparγ, resulting in increased
FA import and biosynthesis (3–5). Secondly, ablation of GH-
stimulated hepatic IGF1 release causes elevated circulating GH
that induces expression of adipose tissue lipases, adipose tissue
lipid mobilization, and lipid flux to the liver (5).
Because Dlk1 is expressed at very high levels in pituitary soma-
totrophs (Fig. 1) (24), we asked whether the GH axis was modified in
WT/TG mice. In WT/TG mice, GH gene expression was elevated in
whole anterior glands from chow-fed mice and those fed a HFD
(Fig. 5A). Another somatotroph marker, the growth hormone-re-
leasing hormone receptor (GHRHR) also had elevated expression,
but no consistent change in markers for other pituitary cell types,
Fig. 3. Dlk1-overexpressing mice are capable of adipose expansion and are
resistant to hepatosteatosis, on an obesogenic genetic background. Body
weights of WT ob/ob and WT/TG ob/ob mice from 3–24 wk of age, males (A),
n ≥ 6 and females (B), n ≥ 5. (C) Body composition of male mice at 24 wk, n as
in A. (D) Liver weight in WT/TG ob/ob mice compared with WT ob/ob mice as
a total weight or % body weight, n ≥ 6 males. (E) H&E staining of repre-
sentative liver sections from fasted male (four, Left) and female (four, Right)
mice at 24 wk at 200× magnification. TAG deposition appears as circular
“empty” droplets. Values are mean ± SEM, *P < 0.05 byMann–Whitney U test.
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including thyrotrophs [thyroid hormone receptor beta (THRβ)],
lactotrophs (Prolactin), or corticotrophs [(Pro-opiomelanocortin
(POMC)], was observed (Fig. 5A). HFD-fed WT/TGmale mice also
had elevated serumGH, with a trend for increased circulating GH in
chow-fed males, and serum GH was elevated in females (Fig. 5B).
Other neuroendocrine axes were not perturbed in WT/TG mice
under unstimulated conditions (Table S6).
Circulating IGF1 levels tracked GH serum levels (Fig. 5B),
indicating that the liver responded appropriately to elevated
GH by increasing IGF1 secretion. The protection from hep-
atosteatosis observed in WT/TG mice is therefore consistent
with the elevated circulating GH acting on the liver to suppress
fatty-acid translocation and lipogenesis.
Raised IGF1 normally feeds back centrally to inhibit GH re-
lease, maintaining homeostasis of the GH axis. To test whether
DLK1 overexpression was causing resistance to IGF1 feedback,
we generated a proxy measure of IGF1 sensitivity by dividing
circulating GH values by circulating IGF1 levels. We found that
WT/TG mice had an elevated GH:IGF1 ratio, consistent with
IGF1 resistance (Fig. 5C). To investigate this mechanism further,
we examined the proximal signaling events in the IGF1 pathway.
Whole pituitary explants were isolated from adult mice, in-
cubated without serum, and then stimulated with IGF1. In WT
mice, IGF1 stimulation caused the expected robust phosphory-
lation of AKT, which was inhibited when the explants were also
treated with the ectodomain of DLK1 (Fig. 5D). In pituitary
explants derived from WT/TG mice, which express high levels of
membrane-bound DLK1 (Fig. 1D), IGF1 stimulation caused an
attenuated AKT phosphorylation signal, and the addition of the
DLK1 ectodomain did not suppress signal transduction further
(Fig. 5D). These data demonstrate that both local and secreted
DLK1 are able to inhibit IGF1 signaling and cause elevated GH
expression due to a defect in negative feedback control.
Muscle Fuel Use and Energy Expenditure Are Altered in Dlk1-
Overexpressing Mice. During periods of fasting, FFAs are used
as fuel particularly by the muscles. Elevated circulating GH
levels in adults are promoted by fasting and cause a switch of fuel
use in peripheral tissues from carbohydrates to fats (2), in part by
regulating Pdk4 (22, 32). Pdk4 encodes pyruvate dehydrogenase
complex (PDC) kinase, a negative regulator of PDC that regu-
lates the entry of glycolytic products into the tricarboxylic acid
cycle. We found that transcription of Pdk4 was elevated in WT/
TG muscle, consistent with increased GH and elevated skeletal
FA oxidation (Fig. 6A). Consistently, when HFD mice were
evaluated by indirect calorimetry after an overnight fast, WT/TG
mice had the expected decrease in respiratory exchange ratio
(Fig. 6B), indicating an increase in lipid oxidation for energy
production. We also observed increased oxygen consumption
(Fig. 6C), indicative of increased energy expenditure. We saw no
differences in body temperature between the two groups (Fig.
6E), and UCP1 expression in brown adipose tissue (BAT) was
not significantly altered between the two genotypes (Fig. S4). We
concluded that the phenotype of DLK1-overexpressing mice was
Fig. 4. Elevated DLK1 protects against diet-induced steatosis by decreasing
hepatic lipogenesis. (A) H&E staining of representative sections from fasted
male mice at 24 wk fed on a HFD, at 40× and 200× magnification. (B and C)
RT-qPCR of liver genes from WT and WT/TG animals fed a chow or HFD at
24 wk (males, fasted for 16 h), relative to WT chow = 1.0, mean ± SEM, n > 7
per genotype. *P < 0.05, **P < 0.01 by Mann–Whitney U test. (D) Western
blotting of liver lysates frommice in B. Mean normalized values are shown as
text. GTT (E) and ITT (F) on 6-mo-old male mice on a HFD. WT/TG was
compared with WT littermates by one-way ANOVA with Bonferroni’s post
hoc test. WT, n = 9; WT/TG, n = 8. *P < 0.05, **P < 0.01. Error bars show SEM.
Fig. 5. Dlk1-overexpressing mice have elevated pituitary growth hormone
secretion as a result of local resistance to IGF1 feedback. (A) RT-qPCR of
anterior pituitary genes in WT and WT/TG animals fed a chow or HFD at
24 wk (fasted for 16 h, 70C mice), relative to WT chow = 1.0. WT and WT/TG,
n = 7 per genotype. Prl, prolactin. (B) Serum GH (Upper) and IGF1 (Lower) in 16-h
fasted chow and HFD-fed mice, measured between 1000 hours and 1200 hours,
n = 6–15 per sex per genotype. *P < 0.05, **P < 0.01 by Student’s t-test. (C) Ratio
of GH:IGF1 levels from all WT and WT/TG mice above (n = 33 WT and 32 WT/TG,
males and females combined because no significant difference was found be-
tween them). **P < 0.01 by Mann–Whitney U test. (D) Western blot of AKT
phosphorylation after IGF (I) or IGF1 plus DLK1 (ID) stimulation of pituitary
explants from WT and WT/TG mice (Upper). The level of phosphorylation was
normalised to total protein levels and charted (Lower), compared by one-way
ANOVA with Bonferroni’s multiple comparison test, **P < 0.01, ***P < 0.001.











consistent with a shift in fuel use toward muscle fatty acid oxi-
dation, due to elevated circulating GH.
Discussion
In this study, we report for the first time, to our knowledge, that
overexpression of Dlk1 from endogenous control elements can
prevent hepatosteatosis by modulation of the growth hormone
pathway. By generating an experimental model in which the normal
expression pattern of the gene is preserved, but expression dosage
was increased, we were able to demonstrate previously unidentified
effects of this protein on whole-body energy homeostasis.
In Dlk1-TG mice, we did not observe a defect in adult adipocyte
expansion in response to positive energy balance. This result was
surprising because, in cell culture models, preadipocytes of both
embryonic and adult origin are inhibited by treatment with the DLK1
ectodomain (12, 33). In addition, transgenic mice overexpressing
soluble DLK1 from ectopic promoters have defective WAT differ-
entiation, leading to a failure of WAT expansion, elevated serum
lipids, and impaired glucose tolerance with insulin resistance (13, 14).
The 70-kb BAC transgenic mice differ from these previous
models because the transgene recapitulates the endogenous spa-
tiotemporal expression pattern of Dlk1, as well as causing over-
expression of both ectodomain and membrane-tethered forms of
the protein. Finally, quantification of the amount of circulating
DLK1 was not reported for the previous models whereas we have
shown that serum DLK1 levels are at four to seven times WT
levels in our three independent transgenic lines. Comparison of
the phenotypes of mice with elevated serum DLK1 (13, 14) to
entopic overexpression of all isoforms (this study) further rein-
forces recent findings that correct localization and dosage of both
membrane-tethered and soluble DLK1 are necessary for this im-
portant protein to produce its biological effects (16, 17).
Our results indicate that, in the context of positive energy
balance, the dosage of DLK1 modifies well-established pathways
of physiological adaptation that abrogate the toxic effects of
excess nutrients. The protection from steatosis conferred by el-
evated DLK1 was apparent in both a dietary obesity model, and
also after genetic ablation of leptin (ob/ob mice). The reduction
in steatosis was not secondary to an alteration in WAT because
leptin-deficient mice with or without the Dlk1-transgene had
identical body composition, but TAG deposition in the liver was
substantially reduced in the WT/TG ob/ob. Elevated DLK1 was
protective against hepatosteatosis by reducing expression of
hepatic lipid import and synthesis genes. In addition, muscles
from Dlk1 transgenic animals had elevated expression of genes
that promote fatty-acid oxidation. Together, these gene-expres-
sion changes caused a shift in whole body fuel utilization away
from glucose and toward fatty acids via elevated GH signaling.
We found that elevated DLK1 caused increased expression of GH
mRNA in the adult pituitary gland and that this rise was accompa-
nied by increased circulating GH levels. Experiments in rat primary
pituitary cell cultures conducted over 25 y ago demonstrated that
IGF1 suppresses GH production by reducing its rate of transcription
(34). More recently, direct evidence for IGF1 feedback to the pitu-
itary was provided by a genetic model of ablated IGF1 signaling in
somatotrophs (the SIGFKOmouse) (35). In this model, lack of IGF1
receptors in somatotrophs resulted in a two- to threefold increase in
circulating GH (35). Consistent with these data, we demonstrated
that isolated pituitary explants from DLK1-overexpressing mice were
refractory to IGF1 signaling. The mechanism by which IGF1 sig-
naling feeds back to GH transcription is not fully understood but is
known to be dependent on the binding of POUF1/CREB binding
protein (CBP) to the GH promoter (36). IGF1 treatment of pituitary
cells reduces Pit1 transcription, thus reducing the bioavailability of
POUF1 (37), and reduces CREB binding to the GH promoter by
posttranscriptional mechanisms (36).
Several previous studies have implicated DLK1 in GH regu-
lation (38–41), and also conversely GH in the regulation of DLK1
(42–44). Notably, a recent study reported a reduction in GH se-
cretion after Dlk1 deletion (40). However, a somatotroph-specific
deletion of Dlk1 did not alter steady-state GH transcription,
consistent with extrapituitary signaling mechanisms being in-
volved (39). Because we were able to demonstrate IGF1 re-
sistance in isolated pituitary explants in the presence of elevated
DLK1, we propose that it is under normal circumstances of high
DLK1 dosage that this molecule is exerting its biological effect.
Increased GH production in Dlk1-TG mice caused some, but
not all, of the expected phenotypes of enhanced GH signaling; as
predicted, Dlk1-TG mice had reduced adipose tissue accumula-
tion (45), had elevated expression of genes in the muscle that
promote FA oxidation (22), and were protected from hep-
atosteatosis by reducing the expression of genes controlling lipid
import (CD36) and synthesis (Srebp1c and Pparγ) (4). In con-
trast, the Dlk1-TG mice displayed moderately improved insulin
sensitivity rather than the insulin resistance predicted by multiple
models of GH signaling ablation (45). In addition, linear growth
was not affected in our model. Recent experiments using con-
ditional targeting of the GH receptor have highlighted that its
concerted actions on multiple tissues are necessary for the full
spectrum of GH action, and that timings of GH action are also
crucial, especially to mediate its growth effects (46). Importantly,
loss of GH signaling in adipose tissue affects body composition
without alterations to glucose homeostasis or growth (46); and he-
patic steatosis can occur in the absence of alterations to whole-body
glucose homeostasis (4). We speculate that the moderate increase
in GH in the Dlk1-TG mice is sufficient to modify fuel utilization by
peripheral tissues without large changes to glucose homeostasis or
growth. In support of this interpretation of our data, the reported
phenotype of SIGFRKO mice is remarkably similar to that of the
DLK1-overexpression model described here: they exhibit moder-
ately elevated expression of GH and GHRHR mRNA, as well as
circulating GH levels, and increased serum IGF1. Moreover,
SIGFRKO mice have normal linear growth but reduced WAT
deposition, and no impairment in glucose homeostasis (35). How-
ever, it is possible that DLK1 may have additional actions on fuel
homeostasis that modify the diabetogenic effects of GH.
Our work highlights the possibility that selective pressures may
be acting on Dlk1 to regulate its dosage during life-history periods
when enhanced peripheral lipid oxidation is beneficial for survival:
during embryogenesis, during suckling, and in the mother during
pregnancy. These are all periods of life when lipogenesis may be
inhibited and tissue FA oxidation promoted to spare scarce glu-
cose for growth (47). We propose that the normal function of
DLK1 is to modulate the GH axis to shift the metabolic mode of
Fig. 6. Muscle fuel use and energy expenditure are altered in Dlk1-over-
expressingmice. (A) RT qPCR ofmuscle genes inWT andWT/TG animals fed a HFD
at 24 wk, measured by WT/TG (70C) male mice fasted for 16 h, n = 7 per geno-
type, on mixed soleus/gastrocnemius muscle. (B–D) Indirect calorimetry on mice
fed a HFD, average respiratory exchange ratio (RER) (B), oxygen consumption (C),
and CO2 production (D) after a 16-h fast in WT and WT/TG mice, presented per
gram body mass. n = 7 WT and 9 WT/TG. (E) Body temperature evaluation per-
formed on mice in B–D. Values are mean ± SEM. All comparisons between WT
andWT/TG (A–E) were performed byMann-Whitney U test, *P < 0.05, **P < 0.01.
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the organism toward peripheral FA oxidation and away from lipid
storage. Therefore, disruption of DLK1 dosage may have impor-
tant consequences for energy homeostasis and metabolic disease.
Experimental Procedures
Breeding of Transgenic Animals. All experiments involving mice were carried out
in accordance with UK Government Home Office licensing procedures. The
generation of the Dlk1-TG BAC transgenic lines (70A, 70B, and 70C) was de-
scribed in ref. 18. We crossed 70C hemizygous transgenic mice with heterozy-
gous ob/+ (Lepob/Lep+) mice on a C57BL/6 background (29) to obtain mice
hemizygous for the 70C transgene and homozygous for the leptin point mu-
tation (+/70C_Lepob/Lepob), along with control littermates (+/+_Lepob/Lepob).
Animals were housed at a density of three to four per cage in a temperature-
controlled room (20–22 °C) with a 12-h light/dark cycle. Chow diet provided 11%
energy from fats (SDS RM3, LBS), and the HFD provided 45% (D12451; Research
Diets Inc.). Food and water were available ad libitum unless otherwise noted.
Body Composition, Indirect Calorimetry, and Body Temperature. Dual-energy
X-ray absorptiometry (DEXA; Lunar Corporation, www.lunarcorp.com) was
used to measure body composition. Oxygen consumption was measured in 24-
wk-old transgenic and WT mice from the HFD cohort after an overnight fast,
by an OXYMAX System 4.93 indirect calorimeter (Columbus Instruments) as
described previously (48). Body temperature values represent the mean of four
rectal temperature measurements over a 2-wk interval between 1400 hours
and 1600 hours with a TES-319 digital thermometer (TES Electronic Corp.).
Pituitary Explant Culture and Stimulations. Whole pituitaries were dissected
from 6-mo-old female mice into HBSS, cut in half, and then transferred to
serum-free DMEM and incubated at 37 °C for 4 h with 5% CO2 in 48-well
dishes. The medium was changed to fresh serum-free DMEM, and then IGF1
(50 nM; Sigma-Aldrich) alone or IGF1 plus DLK1 (100 ng/mL; R&D Systems)
was added to one half of each pituitary. After 10 min, the explants were
rinsed and snap frozen. Before gel electrophoresis for Western blotting,
explants were completely homogenized in Laemmli buffer with DTT.
Statistical Analysis. All statistical tests were performed using the GraphPad
Prism Software, version 4.00 for Windows (GraphPad Software, www.
graphpad.com).
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